This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo

Non Small Cell Lung Cancer

THE FIRST DUAL IMMUNOTHERAPY IN 1L NSCLC

View indication details

  • OPDIVO in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.
Expert opinion

NEW

Prof. Martin Reck (Germany)
interviewed by Prof. Christophe
Dooms (UZ Leuven) on CheckMate
9LA update at 5 years

Where is the highest unmet
medical need in 1L mNSCLC?

BTOS 2023 BMS symposium
with Dr Deschepper

ECLIPSE webinar series for continuous I-O learning via live peer-to-peer clinical practice exchanges

Product information

A short video on
the rationale of combining
OPDIVO and YERVOY
in collaboration with
P. Coulie

Dosing scheme
OPDIVO+YERVOY
+ 2 CT cycles
in 1L NSCLC

Practical user guide
based on OPDIVO SmPC

Patient & nurse materials

A diary for your patients treated with
OPDIVO + YERVOY

www.immunooncology.be

An educational website
on immunotherapy for your
nurses and your patients

Patient brochure
with practical information
on immunotherapy

Patient alert card
OPDIVO

Useful links

1L NSCLC, first-line non small cell lung cancer; CT, chemotherapy; irAE(s), immune-related adverse events(s)

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.